A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing

NCT ID: NCT03133650

Last Updated: 2025-04-11

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-04-26
• Study Completion Date: 2026-02-23

Brief Summary

The purpose of this study is to establish the highest dose of laser light for WST-11 VTP to treat obstruction from esophageal cancer that can be safely given.

Conditions

Esophagogastric Cancer; Moderate to Severe Dysphagia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Vascular-targeted photodynamic therapy (VTP) using WST11

Participants will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes, during an endoscopy procedure, followed by immediate laser light application.

Group Type: EXPERIMENTAL

WST 11-mediated VTP therapy

Intervention Type: DRUG

Administration of WST11 in conjunction with endoscopic illumination at 753 nm emitted by a diode laser and administered to the participant by optical fibre catheters (cylindrical light diffusers) and a standard upper GI endoscope.

Interventions

WST 11-mediated VTP therapy

Administration of WST11 in conjunction with endoscopic illumination at 753 nm emitted by a diode laser and administered to the participant by optical fibre catheters (cylindrical light diffusers) and a standard upper GI endoscope.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age 18 or older
• Confirmed tissue diagnosis of esophageal squamous cell cancer, adenocarcinoma or poorly differentiated carcinoma, with pathology reviewed at MSKCC
• Has incurable disease defined as at least one of the following:

• Presence of metastases to other organs (Stage IV), now or previously
• Has locally advanced disease and are not candidates for surgery or more radiation treatment
• Has received the maximal radiation therapy to the primary site, or has been assessed by radiation oncology as not being a candidate for chemoradiation therapy.
• Karnofsky performance status >/= 50%
• No endoluminal stent in place at the time of treatment
• Previous esophageal dilation is permitted, provided the patient has developed recurrent dysphagia since that procedure
• Patients should not have received any systemic therapy (including chemotherapy, biologic therapy or immunotherapy) </= 7 days prior to treatment
• Prior radiation or surgery to the esophagus is permitted for patients with locally recurrent/persistent disease
• Patients on prophylactic or full-dose anticoagulation are eligible, provided the treating physician believes it is safe to temporarily withhold anticoagulation (see Section 9.2)
• Adequate organ function defined at baseline as:

• ANC ≥1,000/ L
• Platelets ≥75,000/ L
• Hb ≥8.5 g/dl
• INR ≤1.5 (except for patients who are on full-dose warfarin)
• Calculated creatinine clearance ≥50 ml/min (using Cockcroft-Gault method)
• Total serum bilirubin ≤1.5 mg/dL, or </= 2.5 mg/dL for patients with a known history of Gilbert's syndrome
• AST/ALT ≤5× upper limit of normal
• Able to provide written informed consent

Exclusion Criteria

• Pregnant or breast-feeding women. Women of childbearing potential (WOCBP) must undergo a negative pregnancy test (either serum or urine) prior to study entry. Both sexes must use contraception while on study. WOCBP include:

• Any woman who has experienced menarche and who has not undergone surgical sterilization (hysterectomy, bilateral tubal ligation or oophorectomy) or who is not post-menopausal (defined as amenorrheic ≥12 consecutive months)
• Women on hormone replacement therapy with documented serum follicle stimulating hormone level > 35 mIU/ml
• Women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as intrauterine device or barrier methods to prevent pregnancy or are practicing abstinence of where the partner is sterile
• T4 tumors with involvement of any adjacent structure, including the trachea, aorta or pleura
• Prior history of esophageal perforation
• Any other medical or psychiatric comorbidities, including decompensated heart failure, unstable angina or coronary artery disease or severe pulmonary disease, that, in the opinion of the study investigator, would make the patient a poor candidate for the study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Weizmann Institute of Science

OTHER

Sponsor Role: collaborator

Steba Biotech S.A.

OTHER

Sponsor Role: collaborator

Memorial Sloan Kettering Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hans Gerdes, MD

Role: PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Locations

Memorial Sloan - Kettering Cancer Center

New York, New York, United States

Weill Cornell Medical Center (Data Analysis Only)

New York, New York, United States

Weizmann Institute of Science

Rehovot, , Israel

Countries

United States; Israel

Related Links

http://www.mskcc.org/

Memorial Sloan Kettering Cancer Center

Other Identifiers

15-319

Identifier Type: -

Identifier Source: org_study_id